XML 21 R17.htm IDEA: XBRL DOCUMENT v3.2.0.727
Acquisition of Totipotent RX (Details)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended
Feb. 28, 2014
Subsidiary
Feb. 18, 2014
USD ($)
shares
Dec. 31, 2013
USD ($)
$ / shares
Dec. 31, 2013
USD ($)
$ / shares
Dec. 31, 2014
USD ($)
Jun. 30, 2014
USD ($)
Fair value of liabilities assumed [Abstract]            
Goodwill         $ 13,195 $ 13,254
TotipotentRX Corporation [Member]            
Business Acquisition [Line Items]            
Number of wholly owned subsidiaries | Subsidiary 2          
Acquisition related costs     $ 563 $ 1,241    
Aggregate number of shares issued (in shares) | shares   12,490,841        
Percentage of common stock issued to acquiree shareholders (in hundredths)   38.00%        
Number of convertible shares in exchange of warrants issued (in shares) | shares   61,020        
Business acquisition carrying amount of equipment acquired   $ 59        
Purchase Price [Abstract]            
ThermoGenesis common shares and warrants   27,287        
Fair value of assets acquired [Abstract]            
Cash   351        
Receivables   171        
Inventories   191        
Clinical protocols   19,870        
Other intangible assets   2,187        
Equipment   384        
Other assets   132        
Total assets   23,286        
Fair value of liabilities assumed [Abstract]            
Accounts payable   514        
Related party notes payable   337        
Deferred tax liability   8,048        
Other liabilities   295        
Total liabilities   9,194        
Net assets acquired   14,092        
Goodwill   $ 13,195        
Supplemental Pro Forma Data [Abstract]            
Net revenues     4,731 8,639    
Net loss     $ (1,323) $ (3,437)    
Basic and diluted net loss per common share (in dollars per share) | $ / shares     $ (0.05) $ (0.12)    
TotipotentRX Corporation [Member] | Nonrecurring Merger-related Costs [Member]            
Supplemental Pro Forma Data [Abstract]            
Nonrecurring expenses directly attributable to merger     $ 622 $ 1,402